ClinicalTrials.gg
RecruitingNCT00107289Updated May 29, 2026

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

A Phase 2 interventional study of iobenguane I 131 in Neuroblastoma and Pheochromocytoma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2006; still recruiting 20 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center — 5 open to participants now, 10 under way, none of them phase 3. Neuroblastoma · Memorial Sloan Kettering Cancer Center.

Planned enrollment
4th of 37
200 · median 45
Started
2006
with 2 others
Phase 2
22 of 51
4 open now
Registered
16th of 51
by date

Among the 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center, this one is the 4th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2006, is one of 22 in phase 2, and was the 16th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

5 of the 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Neuroblastoma by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this research study is to find how active and safe 131 I-MIBG is in patients with resistant neuroblastoma, malignant pheochromocytoma and malignant paraganglioma.

03

Conditions studied

  • Neuroblastoma
  • Pheochromocytoma

Keywords

  • metastatic pheochromocytoma
  • recurrent pheochromocytoma
  • regional pheochromocytoma
  • recurrent neuroblastoma
  • 04-148
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria for NB:

  • Patients must have the diagnosis of NB in accordance with the International Criteria, i.e., either histopathology (confirmed by the MSKCC Department of Pathology) or BM involvement plus elevated urinary catecholamines.
  • Must have a history of tumor progression or recurrence or failure to achieve complete response with standard therapy.
  • Patients must have MIBG-avid NB and evaluable disease on MIBG scan at time of enrollment on protocol
  • Prior Therapy: At least 2 weeks should have elapsed since any biologic therapy. Three weeks should have elapsed since last dose of chemotherapy.
  • Age >1 year
  • Determination that radiation safety restrictions during therapy period can be implemented.
  • Stem cells: Patients for high does must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment. Patients for low dose do not require cryopreserved autologous hematopoietic stem cell product available. The minimum dose for peripheral blood stem cells is 2 X106 CD34+ cells/kg.
  • Minimum of eight weeks
  • Signed indicating awareness of the nature of this program.

Inclusion criteria for malignant CCT:

  • Patients must have the diagnosis of malignant CCT i.e. malignant pheochromocytoma or malignant paraganglioma
  • Patients must have MIBG-avid malignant CCT and evaluable disease on MIBG scan at time of enrollment on protocol
  • Prior Therapy: At least 2 weeks should have elapsed since any biologic therapy. Three weeks should have elapsed since last dose of chemotherapy.
  • Age between 1 and 21 years and able to cooperate with radiation safety restrictions during therapy period
  • Stem cells: Patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment. The minimum dose for peripheral blood stem cells is 2 X106 CD34+ cells/kg.
  • Minimum life expectancy of eight weeks.
  • Signed informed consent indicating awareness of the investigational nature of this program.

Exclusion Criteria:

  • Severe major organ toxicity. Specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less. A grade 3 hearing deficit is acceptable.
  • Active serious infections not controlled by antibiotics.
  • Pregnant women are excluded for fear of danger to the fetus. Therefore negative pregnancy test is required for all women of child-bearing age, and appropriate is used during the study period.
  • Inability or unwillingness to comply with radiation safety procedures or protocol requirements.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Radiation

    Patients will be treated with IV 131I-MIBG using 1-2 high dose(s) or up to 16 low doses. Thyroid protection is commenced seven days (+/-2 days) prior to administration of 131I-MIBG and continued for up to 42 days after each 131I-MIBG treatment. Given that this is an open access protocol, re-enrollment is allowed per PI discretion. Patients who received this treatment previously are allowed to be re-enrolled if they meet the eligibility criteria. Re-enrollment can be to the same arm previously treated on (high dose versus low dose) or to the other arm. Patients will not be eligible for re-enrollment if they have already received 16 low doses or 4 high doses of 131I-MIBG.

    Drug: iobenguane I 131

Interventions

  • Drug3-IodobenzylguanidineStudies of 3-Iodobenzylguanidine3-Iodobenzylguanidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A single dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) IV over 30 minutes to 4 hours or for 15 minutes for smaller patients on day 0. Patients undergo radiation dosimetry following the first dose of \^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) 6-8 weeks after the first dose. In some scenarios, extended time will be allowed before the second dose of 131I-MIBG for additional recovery and possible bridging therapy. If response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation. After completion of study treatment, patients are followed at 4-6 weeks after \^131I-MIBG administration and then every 3 months for up to 1 year. Once patients are off treatment on this protocol, they will begin long term follow up through 5 years from enrollment.

06

What researchers measure

Primary outcomes

  1. Response (complete or partial)

    Time frame: 2 years

Secondary outcomes

  1. Correlation between tumor self-absorbed dose and response and tumor volume decrease

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Ellen Basu, MD, PhD · Contact212-639-5204
    • Shakeel Modak, MD · Contact212-639-7623
    • Ellen Basu, MD, PhD · Principal investigator
08

References and documents

Publications

  • Chu BP, Horan C, Basu E, Dauer L, Williamson M, Carrasquillo JA, Pandit-Taskar N, Modak S. Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms. Pediatr Blood Cancer. 2016 May;63(5):801-7. doi: 10.1002/pbc.25892. Epub 2016 Jan 15. PubMed 26773712 ↗
  • Modak S, Zanzonico P, Carrasquillo JA, Kushner BH, Kramer K, Cheung NK, Larson SM, Pandit-Taskar N. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. J Nucl Med. 2016 Feb;57(2):231-7. doi: 10.2967/jnumed.115.161752. Epub 2016 Jan 7. PubMed 26742708 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2006 (actual). Primary completion is estimated for May 2027, 252 months after the start.

Of 62 non-industry phase 2 interventional studies under Neuroblastoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 99. This study's planned 252 months is above that.

Counting every sponsor, half of 67 studies reached it within 74 months; a quarter within 52 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 5, 2005
First posted
Apr 6, 2005
StartActual
May 2006
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00107289
Responsible party
Sponsor
First posted
Apr 6, 2005
Start date
May 2006
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
May 29, 2026

Study contacts

Ellen Basu, MD, PhD
Contact
212-639-5204
Shakeel Modak, MD
Contact
212-639-7623
Ellen Basu, MD, PhD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 3-Iodobenzylguanidine

Start the discussion